226 related articles for article (PubMed ID: 8883418)
1. Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.
Gerl A; Clemm C; Schmeller N; Hartenstein R; Lamerz R; Wilmanns W
Br J Cancer; 1996 Oct; 74(8):1280-5. PubMed ID: 8883418
[TBL] [Abstract][Full Text] [Related]
2. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
3. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
Fléchon A; Biron P; Philip I; Blay JY; Droz JP
Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
[TBL] [Abstract][Full Text] [Related]
4. Late relapse of germ cell tumors after cisplatin-based chemotherapy.
Gerl A; Clemm C; Schmeller N; Hentrich M; Lamerz R; Wilmanns W
Ann Oncol; 1997 Jan; 8(1):41-7. PubMed ID: 9093706
[TBL] [Abstract][Full Text] [Related]
5. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
6. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors.
Hartmann JT; Nichols CR; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Kanz L; Einhorn L; Bokemeyer C
Ann Oncol; 2002 Jul; 13(7):1017-28. PubMed ID: 12176779
[TBL] [Abstract][Full Text] [Related]
7. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
9. Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy.
Hollender A; Stenwig EA; Ous S; Fosså SD
Eur Urol; 1997; 31(2):141-7. PubMed ID: 9076455
[TBL] [Abstract][Full Text] [Related]
10. Platinum-based chemotherapy of primary extragonadal germ cell tumours: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Aravantinos G; Visvikis A; Bakoyiannis C; Halikia A; Kalofonos C; Kosmidis P; Skarlos D; Fountzilas G
Oncology; 1999 Jul; 57(1):1-9. PubMed ID: 10394118
[TBL] [Abstract][Full Text] [Related]
11. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
Bhala N; Coleman JM; Radstone CR; Horsman JM; George J; Hancock BW; Hatton MQ; Coleman RE
Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):40-7. PubMed ID: 14768754
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-based chemotherapy in advanced seminoma: the Institut Gustave Roussy experience.
Culine S; Abs L; Terrier-Lacombe MJ; Théodore C; Wibault P; Droz JP
Eur J Cancer; 1998 Feb; 34(3):353-8. PubMed ID: 9640221
[TBL] [Abstract][Full Text] [Related]
13. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis.
Hartmann JT; Einhorn L; Nichols CR; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Schmoll HJ; Kanz L; Bokemeyer C
J Clin Oncol; 2001 Mar; 19(6):1641-8. PubMed ID: 11250992
[TBL] [Abstract][Full Text] [Related]
14. [Observation policy for residual masses after chemotherapy for gonadal and extra-gonadal germ cell tumors].
Takizawa A; Miura T; Fujinami K; Osada Y
Hinyokika Kiyo; 2005 Apr; 51(4):247-51. PubMed ID: 15912783
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin-based chemotherapy of primary extragonadal germ cell tumors. A single institution experience.
Gerl A; Clemm C; Lamerz R; Wilmanns W
Cancer; 1996 Feb; 77(3):526-32. PubMed ID: 8630961
[TBL] [Abstract][Full Text] [Related]
17. Extragonadal germ cell tumors: relation to testicular neoplasia and management options.
Bokemeyer C; Hartmann JT; Fossa SD; Droz JP; Schmol HJ; Horwich A; Gerl A; Beyer J; Pont J; Kanz L; Nichols CR; Einhorn L
APMIS; 2003 Jan; 111(1):49-59; discussion 59-63. PubMed ID: 12752235
[TBL] [Abstract][Full Text] [Related]
18. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors.
Hartmann JT; Schmoll HJ; Kuczyk MA; Candelaria M; Bokemeyer C
Ann Oncol; 1997 Jun; 8(6):531-8. PubMed ID: 9261521
[TBL] [Abstract][Full Text] [Related]
19. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours.
Hartmann JT; Candelaria M; Kuczyk MA; Schmoll HJ; Bokemeyer C
Eur J Cancer; 1997 May; 33(6):843-7. PubMed ID: 9291803
[TBL] [Abstract][Full Text] [Related]
20. Primary chemotherapy for stage 2 testis cancer.
Abratt RP; McAdam GL; Pontin AR; Barnes RD; Ball HS
S Afr J Surg; 1997 Nov; 35(4):203-5; discussion 205-6. PubMed ID: 9540399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]